Skip to main
COCH

COCH Stock Forecast & Price Target

COCH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Envoy Medical is a hearing health company with a fully implanted active middle ear implant (FI-AMEI) and an investigational cochlear implant in its product portfolio. Their revenue comes primarily from the sale of FI-AMEI implants. The company has successfully completed enrollment for their pivotal trial for their cochlear implant and expects to have all patients complete their 12-month visits by April 2027, with a potential approval window of year-end 2027 to mid-2028. With a positive 10-person team dedicated to key market targets and a potential increase in market adoption due to the fully implanted option, Envoy has significant potential for success in the hearing health market.

Bears say

Envoy Medical is facing several challenges with their leading product, the Esteem FI-AMEI implant, as well as their investigational cochlear implant, Acclaim CI. With limited differentiation between cochlear implants and a complex pathway to adoption, there are concerns about underutilization and potential delays in regulatory approval for the Acclaim CI. Additionally, the company's financials show a history of significant operating losses and reliance on a single-source supplier, making it vulnerable to potential supply chain disruptions. The company's limited cash position and ongoing legal dispute regarding share redemption create further concerns about its financial stability.

COCH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Envoy Medical Inc (COCH) Forecast

Analysts have given COCH a Strong Buy based on their latest research and market trends.

According to 2 analysts, COCH has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Envoy Medical Inc (COCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.